Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Abbott Expands Agreement with GlaxoSmithKline to Develop Companion Diagnostic

By Labmedica International staff writers
Posted on 15 Dec 2011
Abbott (Abbott Park, IL, USA) will expand its existing agreement with GlaxoSmithKline Biologicals (GSK; Brentford, United Kingdom) to include the development of an additional companion diagnostic test for a cancer immunotherapy antigen.

The existing agreements between the two companies focused on the development of PCR tests to screen non-small-cell lung cancer and melanoma tumors for expression of the MAGE-A3 antigen. MAGE-A3 is a tumor-specific antigen that is expressed in a large variety of cancers, including melanoma, non-small-cell lung, head and neck, and bladder cancer, with no expression in normal cells. Expression of the MAGE-A3 gene has been observed in testicular cells but without antigen presentation capabilities.

Under the expanded agreement, Abbott will develop a polymerase chain reaction (PCR) test for use on the Abbott m2000rt instrument to screen non-small-cell lung cancer tumors for expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69 % of non-small-cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.

Abbott is a pioneer in the use of molecular tests based on PCR and fluorescence in situ hybridization (FISH) technologies to aid clinicians in the selection of appropriate pharmacogenomic therapies.

GSK’s Antigen Specific Cancer Immunotherapy Program (ASCI) is investigated in the clinic to support their use to reduce the risk of tumor recurrence following surgery, or to impact tumor growth in an early metastatic setting. The highly specific mode of action of GSK’s ASCIs allows development of diagnostic tools to aid in selecting patients eligible for the treatment, depending on the expression of the tumor antigens.

Related Links:

Abbott
GlaxoSmithKline Biologicals



DiagCor Bioscience
Sekisui Diagnostics
VIRCELL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The URiSCAN Super Plus reflectance meter (Photo courtesy of YD Diagnostics).

Semiquantitative Urine Dipstick Evaluated for Microalbuminuria Screening

The urine microalbumin test is used as a screening test for the diagnosis of renal complications in diseases, such as diabetic nephropathy, cardiovascular disease, and hypertension. A urine dipstick... Read more

Microbiology

view channel
Image: The adult free-living female Strongyloides stercoralis with a row of eggs within the body of the nematode (Photo courtesy of the CDC - Centers for Disease Control and Prevention).

Rapid Serological Assay Developed for Strongyloidiasis

Several imperfect methods exist for diagnosing strongyloidiasis and stool examination with microscopic identification of larvae considered the gold standard diagnostic procedure, showing good specificity... Read more

Pathology

view channel
Image: The BD Viper LT System for fully automated, integrated molecular testing on a table top analyzer (Photo courtesy of BD Diagnostics).

Modern Methods Accurately Detects Cervical Cancer

The newer Papanicolaou test (Pap tests) and human papilloma virus (HPV) screening more accurately identify precancerous cellular changes that potentially develop into cervical cancer. Compared to a... Read more

Lab Tech.

view channel
Image: RNAscope detects TP63 mRNA expression in human prostate tissue (Photo courtesy of Advanced Cell Diagnostics).

RNA Biomarker Assay Now Manufactured According to Strict ISO Regulatory Criteria

A line of diagnostic kits that measures RNA biomarkers with single-molecule sensitivity is now being manufactured under the stringent requirements of ISO 13485:2003 certification. Advanced Cell Diagnostics, Inc.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.